Clarify Medical Announces Medicare Reimbursement for the First Smartphone-Connected Home Phototherapy System

  • CMS Reimbursement Enables Medicare Patients with Psoriasis to Access
    the Clarify Home Light Therapy System
  • The Clarify System’s Patented Technology Enables Patients to Treat at
    Home with the Same Level of Control and Care That They Receive in the
    Clinic

SAN DIEGO–(BUSINESS WIRE)–Clarify
Medical
today announced that the Clarify Home Light Therapy System,
the company’s innovative smartphone-connected home phototherapy system,
is now covered for Medicare patients with psoriasis, effective
immediately. This decision by U.S. Centers for Medicare & Medicaid
Services (CMS) falls under its longstanding National Coverage
Determination for the treatment of psoriasis, which includes narrowband
ultraviolet B (NB-UVB) phototherapy.

The Clarify
System
, cleared by the FDA in 2017, is indicated for localized
phototherapeutic treatment of dermatologic conditions such as psoriasis,
vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and
leukoderma on all skin types (I-VI). It is the first and only connected
phototherapy system that uses an app on the patient’s own smartphone
(iOS or Android) to manage the dose, frequency, and duration of UVB
light therapy, helping to ensure that patients receive the proper doses
recommended by the American Academy of Dermatology in its published Guidelines
of care for the management of psoriasis and psoriatic arthritis
. The
treatment regimen is prescribed by the patient’s physician but monitored
and controlled by the Clarify System’s cloud-based software, enabling
patients to administer treatment with clinical precision in the
convenience of their homes or while traveling. The connected system
monitors dosing, adherence, compliance, patient progress and
satisfaction.

The Clarify smartphone app syncs to a patented, lightweight, handheld
device which guides patients through delivering targeted narrowband UVB
phototherapy treatments for their specific skin conditions. All
treatment records, including photographs
and patient-reported outcomes, are available to both the patient and the
physician and can be used for evaluation during follow-up visits.
Clarify CarePartners, trained patient support personnel, act as the
first line of support for patients – coaching them on the use of the
system and encouraging treatment adherence – greatly reducing the burden
of these functions on the physician’s practice.

“This is a significant milestone for Clarify and the patients we serve,”
said George Mahaffey, President & CEO of Clarify Medical. “Not only does
this decision enable millions of Medicare beneficiaries to treat their
psoriasis using the Clarify System, but it also enables the Company to
begin establishing coverage with private medical insurance plans, which
we are already pursuing in earnest. Our mission now is to make our
System accessible and affordable for as many patients as possible.”

Clarify Medical is a private San Diego-based medical device company
focused on developing innovative technology, products and services that
improve care for people with chronic skin conditions. Its Clarify Home
Light Therapy System is now available nationally in the US. Learn more
at 
www.clarifymed.com.

Contacts

Media: Teddy Fulham, 626-823-6744, [email protected]

error: Content is protected !!